JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

Benzinga · 1d ago
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.